Bilimsel çalışmalar

Doç. Dr. Murad Gulıyev

68 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. 212eP Optimizing diagnostic approach and steroid use in GI toxicities associated with immune checkpoint inhibitors: A single center experience

    Immuno-Oncology Technology, 2025

    DOI 10.1016/j.iotech.2025.101295 Kaynak: OpenAlex

  2. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim

    Akademisyen Kitabevi eBooks, 2024

    DOI 10.37609/akya.2380 Açık erişimli tam metinKaynak: OpenAlex

  3. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

    Journal of Oncological Sciences, 2024

    DOI 10.37047/jos.2024-102164 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  4. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2330835 PMID 38497444 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  5. Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients

    Medicina, 2024

    DOI 10.3390/medicina60121953 PMID 39768835 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  6. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study

    Breast Cancer Research and Treatment, 2024

    DOI 10.1007/s10549-024-07291-0 PMID 38526689 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  7. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

    European Archives of Oto-Rhino-Laryngology, 2024

    DOI 10.1007/s00405-024-08744-4 PMID 38795147 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  8. The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer

    BMC Cancer, 2024

    DOI 10.1186/s12885-024-13064-1 PMID 39448928 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  9. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors

    Clinical & Translational Oncology, 2024

    DOI 10.1007/s12094-024-03696-x PMID 39225958 3 atıf (Europe PMC) Kaynak: OpenAlex

  10. Could macrocytosis predict survival In advanced breast cancer patients that were treated with CDK 4–6 inhibitors?

    The Breast, 2024

    DOI 10.1016/j.breast.2024.103820 PMID 39405594 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  11. Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer

    Tumori Journal, 2024

    DOI 10.1177/03008916241291989 PMID 39506383 Açık erişimli tam metinKaynak: OpenAlex

  12. 68P Real-world clinical and treatment-related outcomes in specific subgroups of patients with BRAF-positive metastatic melanoma treated with dabrafenib-trametinib: Turkish Oncology Group study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.102297 Kaynak: OpenAlex

  13. 149P HER2-low status and response to neoadjuvant chemotherapy in early breast cancer

    ESMO Open, 2023

    DOI 10.1016/j.esmoop.2023.101488 Açık erişimli tam metinKaynak: OpenAlex

  14. Retrospective Analysis of Prognostic Factors and Survival in Multiple Myeloma Patients Aged 65 Years or Older at Diagnosis in a Real-Life Setting and a Proposed New Staging System

    Blood, 2022

    DOI 10.1182/blood-2022-170159 Kaynak: OpenAlex

  15. Real?world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple?negative breast ancer: A multicenter study by the Turkish Oncology Group

    Kaynak: acibadem.com.tr profil sayfası

  16. Real?world comparison of cabozantinib and sunitinib in advanced non?clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

    Kaynak: acibadem.com.tr profil sayfası

  17. Rethinking adjuvant chemotherapy in colon cancer patients aged ?65: Survival and prognostic factors

    Kaynak: acibadem.com.tr profil sayfası

  18. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

    Kaynak: acibadem.com.tr profil sayfası